ClinicalTrials.gg
CompletedNCT01261741Updated Nov 27, 2013

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

A Phase 2 interventional study of Memantine and Placebo in Memory Disorder, Retention Disorder, Cognitive and Subjective Cognitive Impairment, sponsored by Merz Pharmaceuticals GmbH. Completed at 14 sites in 2 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-27.

Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
299
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Memory Disorders with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Memory Disorders · Germany.

Enrollment
4th of 10
299 · median 205
Started
2010
the only one that year
Phase 2
4 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
Merz Pharmaceuticals GmbH

Among the 13 studies in Memory Disorders with a site in Germany, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 4th registered.

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

Browse Memory Disorders studies →

Open to participants now

1 of the 13 studies in Memory Disorders with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 54 Memory Disorders studies recruiting now, 27 (50%) set no upper age limit and 13 (24%) stop at 75 or younger; 3 take children under 18; 22 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Memory Disorders with a site in Germany, or all of them as a file.
02

Study summary

In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

03

Conditions studied

  • Memory Disorder
  • Retention Disorder, Cognitive
  • Subjective Cognitive Impairment
  • Memory, Concentration or Attention Problems

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjective worsening of memory, concentration or attention problems for longer than 6 months
  • Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject
  • Experience of the memory, concentration or attention problems at least four times per week

Exclusion criteria

Exclusion Criteria:

  • Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia)
  • Significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes
  • History of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
299 participants (actual)

Study arms

  • Experimental
    Memantine

    Drug: Memantine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Each subject will receive memantine 10mg tablets once daily

  • DrugPlacebo

    Each subject will receive matching placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. "Patient Global Impression of Change" (PGI-C) at visit 4

    It is the statistical comparison between the placebo group and the memantine group.The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline to visit 3 and 5 of Patient Global Impression of Change (PGI-C)

    Time frame: 16 weeks

  2. Change from baseline to visit 4 in "Everyday Cognition 39" (ECog 39) total score

    Time frame: 12 weeks

  3. Change from baseline to visit 4 in "Hospital Anxiety and Depression Scale" (HADS) Score

    Time frame: 12 weeks

  4. Change from baseline to visit 3, 4, 5 of "Computer-based Neuropsychological Test Battery (C-NTB) by CogState Ltd.

    Time frame: 16 weeks

07

Study locations

14 sites
  • Universitätsklinikum der RWTH Aachen
    Aachen, 52074, Germany
  • Klinische Forschung Berlin-Mitte
    Berlin-Mitte, 10117, Germany
  • Praxis Dr. Heidenreich
    Böblingen, 71032, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Praxis Dr. Albrecht
    Ellwangen, 73479, Germany
  • Praxis Dr. Reifschneider
    Erbach, 64711, Germany
  • Klinische Forschung Hannover-Mitte
    Hannover, 30159, Germany
  • ZSL Zentrum für medizinische Studien in Leipzig
    Leipzig, 04157, Germany
  • Praxis Dr. Pauls
    München, 80331, Germany
  • Praxis Dr. Kühn
    Oranienburg, 16515, Germany
  • Praxis Dr. Krause
    Wolfratshausen, 82515, Germany
  • Royal United Hospital
    Bath, BA1 3NG, United Kingdom
  • Community Pharmacology Services (CPS)
    Glasgow, G20 0XA, United Kingdom
  • Moorgreen Hospital
    West End, Southampton, SO30 3JB, United Kingdom
08

References and documents

Publications

  • Schulz JB, Acker C, Seitzinger A, Pulte I. Randomized, double-blind, placebo-controlled, multicentre study to investigate memantine in the treatment of memory, concentration, and attention problems (subjective cognitive impairment). Journal of the Neurological Sciences 333 Suppl.1: e332, 2013. doi:10.1016/j.jns.2013.07.1232
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2010
First posted
Dec 16, 2010
Start
Nov 2010
Primary completionActual
Aug 2011
CompletionActual
Sep 2011
Last update
Nov 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01261741
Responsible party
Sponsor
First posted
Dec 16, 2010
Start date
Nov 2010
Primary completion
Aug 2011
Completion
Sep 2011
Last update
Nov 27, 2013

Study contacts

Merz Medical Expert
study director · Merz Pharmaceuticals GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion